China NMPA Drug Inspection - Xian Lijun Pharmaceutical Co., Ltd - Vitamin C tablets

The Ningxia Food and Drug Administration published Announcement No. 04, 2017, on June 9, 2017, detailing the results of its regional drug quality sampling inspections. These inspections were carried out under the "2017 Regional Drug Sampling Inspection Work Plan" and encompassed 96 batches covering 40 distinct drug varieties. The sampled products included 66 chemical drugs and 30 traditional Chinese medicine decoction pieces, sourced from numerous manufacturers such as Shanghai Huayuan Pharmaceutical (Ningxia) Shasai Pharmaceutical Co., Ltd., Xi'an Lijun Pharmaceutical Co., Ltd., and Shandong Xinhua Pharmaceutical Co., Ltd. The regulatory framework for these assessments primarily involved the Chinese Pharmacopoeia (various editions, notably 2015), National Drug Standards, and Ministry of Health Drug Standards. Critically, all 96 batches subjected to inspection were found to be fully compliant with the established quality requirements. As a result, the announcement reported no main violations or issues, and consequently, no specific regulatory actions were required for any of the sampled products or their respective manufacturers. The findings indicate satisfactory adherence to pharmaceutical quality standards within the region during the inspection period.